Table 2.

Factors associated with virological success at 30 months (n = 847)

	Univariate analysis			Multivariate analysis
	OR	95% CI	p	aOR	95% CI	p
HIV-1 DNA: < 3 vs. ≥ 3 log10 copies/million PBMC	1.44	0.99–2.07	0.05	1.57	1.08–2.30	0.02
CD4 count: < 500 vs ≥ 500 cells/mm3	1.11	0.77–1.61	0.58	1.15	0.78–1.68	0.48
Plasma RNA: < 5 vs ≥ 5 log10 copies/ml	1.20	0.82–1.75	0.35
Sex: male vs. female	1.32	0.82–2.15	0.25	1.15	0.69–1.91	0.60
Age: < 35 years vs. ≥ 35 years	0.60	0.42–0.87	0.01	0.62	0.42–0.91	0.01
WHO clinical stage: 1–2 vs. 3–4	0.76	0.39–1.47	0.41
IPT: received vs. not received	1.00	0.69–1.44	0.98
ART regimen
TDF/FTC + LPV/r vs  TDF/FTC + EFV	0.56	0.37–0.85	0.01	0.59	0.39–0.91	0.02
TDF/FTC + AZT vs  TDF/FTC + EFV	1.28	0.59–2.77	0.53	1.41	0.64–3.11	0.40

n number of patients; OR odds ratio; aOR adjusted odds ratio; IPT 6-month isoniazide preventive therapy; CI confidence interval; DNA desoxyribonucleique acid; PBMC peripheral blood mononuclear cells; RNA ribonucleique acid; LPV/r lopinavir/ritonavir; AZT azidothymidine; EFV efavirenz; TDF tenofovir; FTC emtricitabine